Type Size

    Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial

    The authors assessed the safety and efficacy of risedronate, an orally administered third-generation bisphosphonate, in children with the osteogenesis imperfecta.  They found that oral risedronate increased areal BMD and reduced the risk of first and recurrent clinical fractures and the drug was generally well tolerated.

    Read Article

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Policies and Procedures for more details